What’s Actually Happened with ACR in QOF – and Why It Matters

Urine ACR (albumin-to-creatinine ratio) is one of the most clinically important tests in identifying early kidney disease.

It plays a key role in:

• Detecting chronic kidney disease (CKD)
• Stratifying cardiovascular risk
• Guiding treatment decisions

And yet, within the Quality and Outcomes Framework (QOF), its role has quietly shifted.

Which raises an important question:

If ACR is clinically important — why isn’t it a major QOF priority?

ACR in QOF: Always there, but never central

ACR hasn’t disappeared from QOF.

It still exists within:

• CKD pathways
• Diabetes care processes

For example, NICE-linked indicators include measuring ACR alongside eGFR when diagnosing CKD, recognising its role in improving outcomes  .

But importantly:

• ACR has typically been part of process measures
• Not outcome-driven, high-value indicators

And that distinction matters.

The shift in QOF priorities

Recent QOF changes have made one thing clear:

The focus has moved toward measurable outcomes, particularly in cardiovascular disease.

This includes:

• Cholesterol targets
• Blood pressure control
• Statin optimisation

Significant funding and points have been redistributed into these areas, reinforcing their importance in practice  .

In contrast:

ACR has not been strengthened

It has not become a high-incentive metric 

The unintended consequence

This creates a subtle but important dynamic.

QOF is designed to drive behaviour — it directly links clinical activity to financial incentives.

So when ACR is:

• Lower priority
• Process-based
• Less financially incentivised

It can become Less consistently delivered in practice

This is already visible in real-world data.

In diabetes care, urine ACR is one of the most commonly missed processes, often because it requires a separate appointment or additional patient engagement.

The gap between guidance and incentives

This is where the tension sits.

On one hand:

• Clinical guidelines emphasise the importance of ACR
• It is central to risk stratification

On the other:

• QOF does not strongly incentivise it
• Delivery is inconsistent

This creates a familiar pattern in healthcare:

What is clinically important  ≠. What is operationally prioritised

A pathway problem, not just a testing problem

In many practices, ACR testing requires:

• A separate urine sample
• Additional patient engagement
• Another step in the pathway

Compared to blood tests, this introduces:

• Friction
• Drop-off
• Missed opportunities

So even when clinicians understand its importance, delivery becomes the challenge.

Where does this leave ACR?

ACR sits in an interesting position:

• Clinically valuable
• Recommended in guidelines
• But under-incentivised within QOF

Which means its impact depends less on policy — and more on how effectively it can be embedded into real-world pathways.

Final thought

ACR hasn’t been removed from QOF. But it hasn’t been prioritised either. And in a system where incentives shape behaviour, that matters. Because improving outcomes in conditions like CKD and cardiovascular disease isn’t just about focusing on what is measured.

It’s about ensuring that the tests which detect risk early enough to change outcomes are consistently delivered in practice.